The share price has fallen, largely due to the NBI:US falling off a cliff in the last week.. it's that simple, we are following the biotech index down, as we did up from November 23..
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
